



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY



Role of PET/CT in post therapeutic assessment of bronchogenic carcinoma

Thesis

**Submitted for partial fulfillment of the MD Degree in
Radio-diagnosis**

By

Amira Ayman Shaheen
MB.B.Ch, MSc Radiodiagnosis

Under Supervision of

Dr. Ahmed Mostafa Mohammed

**Professor of Radiodiagnosis
Faculty of Medicine - Ain shams University**

Dr. Mennatoallah Hatem Shalaby

**Professor of Radiodiagnosis
Faculty of Medicine - Ain Shams University**

Dr. Ahmed Mohamed Samy Elshimy

**Lecturer of Radiodiagnosis
Faculty of Medicine - Ain Shams University**

**Faculty of Medicine
Ain-Shams University
2020**

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**,
the Most Kind and Most Merciful.*

I can hardly find the words to express my gratitude to **Dr. Ahmed Mostafa Mohammed**, Professor of Radiodiagnosis, Faculty of medicine - Ain shams University, for his supervision, continuous help, encouragement throughout this work.

I would like also to express my sincere appreciation and gratitude to **Dr. Mennatoallah Hatem Shalaby**, Assistant professor of Radiodiagnosis, Faculty of medicine - Ain Shams University, for her continuous directions and support throughout the whole work.

I cannot forget the great help of **Dr. Ahmed Mohamed Samy Elshimy**, Lecturer of Radiodiagnosis, Faculty of medicine - Ain Shams University for his efforts and continuous guidance and support to get this work into light.

Amira Shaheen

List of Contents

Title	Page No.
List of Abbreviations.....	i
List of Tables	ii
List of Figures	iii
Introduction	1
Aim of the Work.....	5
Review of Literature	
Anatomy of the Lungs	6
Pathology of lung cancer	19
Staging of lung cancer	23
Role of PET-CT in Post Therapeutic Assessment of Bronchogenic Carcinoma	28
Patients and Methods.....	45
Results	55
Illustrative Cases	71
Discussion	88
Summary and Conclusion.....	96
References	99
Arabic Summary	—

List of Abbreviations

Abb.	Full term
18 F –FDG.....	18 F-Fluorodeoxeglucose
AJCC	American joint committee on cancer
AUC	Area under curve
COPD.....	Chronic obstructive lung disease
CR.....	Complete response
CT	Computed tomography
EGFR.....	Epidermal Growth Factor Receptor
IASLC.....	International Association for the study of lung cancer
NPV	Negative predictive value
NSCLC	Non small-cell lung cancer
PD	Progressive disease
PET	Positron Emission Tomography
PPV.....	Positive predictive value
PR	Partial response
RECIST	Response Evaluation Criteria in solid tumors
ROC	Receiver operator characteristic
SCLC	Small cell lung cancer
SD	Stable disease,
SUV	Standardized Uptake Value
SUVmax	Maximum Standardized Uptake Value
TNM	Tumor Node Metastasis
UICC.....	Union of international cancer control
WHO.....	World Health Organization

List of Tables

Table No.	Title	Page No.
Table (1):	The new 8 th TNM classification	24
Table (2):	Stages of lung cancer adapted from the 8th Edition of TNM in Lung Cancer (quoted from radiologyassistant.nl.).....	25
Table (3):	RECIST 1.1 criteria for response assessment.	54
Table (4):	Distribution of the lung tumors in the various lung regions	58
Table (5):	T – staging of all tumors	58
Table (6):	Distribution of all patients in the different groups designated according to treatment response.....	60
Table (7):	Comparison of baseline and post – treatment SUV in both Responder and Non-responder groups.....	60
Table (8):	Comparison between pre-treatment SUV, post-treatment SUV and % change in SUV (Δ SUV) of the responder and non-responder groups.....	61
Table (9):	The sensitivities, specificities, positive predictive values (PPV), negative predictive values (NPV), area under curves (AUC) and P values of the optimum threshold values of the post-treatment SUV and SUV for differentiation of responders from non-responders	63
Table (10):	Comparison of baseline and post – treatment SUV in PD, SD, and PR groups	66
Table (11):	Comparison between pre-treatment SUV, post-treatment SUV and % change in SUV (Δ SUV) of the PD, SD and PR groups	67

List of Figures

Fig. No.	Title	Page No.
Fig. (1):	Schematic diagram of the respiratory system showing the upper and lower tracts	7
Fig. (2):	The lobes and fissures of the lungs. The pleurae are shown in blue	10
Fig. (3):	Bronchopulmonary segments	12
Fig. (4):	Aorta, trachea, anterior view	13
Fig. (5):	Lymphatic drainage of the lungs	14
Fig. (6):	Section lower neck	15
Fig. (7):	Section entering thorax	15
Fig. (8):	Section superior mediastinum	15
Fig. (9):	Section aortic arch	15
Fig. (10):	Section level of carina	16
Fig. (11):	Section pulmonary trunk	16
Fig. (12):	Section below carina	16
Fig. (13):	Section just above diaphragm	16
Fig. (14):	Section upper lobe	17
Fig. (15):	Section upper lobe lower level	17
Fig. (16):	Section middle lobe	18
Fig. (17):	Section middle and lower lobes	18
Fig. (18):	Section lower lobe	18
Fig. (19):	Squamous cell carcinoma (epidermoid carcinoma)	20
Fig. (20):	Adenocarcinomas arise peripherally from mucous glands and the cells retain some of the tubular, acinar or papillary differentiation and mucus production	21
Fig. (21):	Large cell carcinoma metastasizes early and may simply be considered to be those cancers which do not fit into the categories above	21

List of Figures Cont...

Fig. No.	Title	Page No.
Fig. (22):	Small (Oat) cell carcinoma, these cells secrete a large amount of polypeptide hormones	22
Fig. (23):	Thoracic PET/CT scans (left) and a PET scan (right), which were performed for the staging of a 57-year-old female patient diagnosed with non-small cell lung cancer.....	31
Fig. (24):	PET/CT images of a 60-year-old male patient diagnosed with non-small cell lung cancer and undergoing radiotherapy	32
Fig. (25):	58-year-old woman with T4N2M0 stage IIIB moderate to poorly differentiated adenocarcinoma in right upper lung lobe show partial metabolic response	35
Fig. (26):	64-year-old woman with stage IV small cell carcinoma of right lower lobe with progression of metastatic disease to bilateral supraclavicular and mediastinal nodes	36
Fig. (27):	66-year-old woman initially diagnosed with stage IIIA disease who underwent neoadjuvant cisplatin, etoposide, and radiation therapy followed by right lower lobe lobectomy and thoracic lymphadenectomy 1 year before.....	39
Fig. (28):	A 68-year-old man with non-small-cell lung cancer with post-obstructive atelectasis and multiple lymph node metastases at initial staging.....	40
Fig. (29):	FDG PET in nodal disease false-positive study.....	42
Fig. (30):	Inflammatory FDG uptake at the needle path site used for RF ablation	43

List of Figures Cont...

Fig. No.	Title	Page No.
Fig. (31):	Bar chart showing the number of males and females in this study.....	55
Fig. (32):	Stacked column chart showing the contribution of males and females in each age group	56
Fig. (33):	Bar chart showing the number of smokers among both female and male patients.....	57
Fig. (34):	Box-and-whisker plots of pre and post-treatment SUV in both responder and non-responder groups	62
Fig. (35):	Box-and-whisker plots of Δ SUV in both responder and non-responder groups	62
Fig. (36):	Receiver operating characteristic curve analyses	65
Fig. (37):	Box-and-whisker plots of pre-treatment SUV in PD, SD, PR and CR groups.....	67
Fig. (38):	Box-and-whisker plots of post-treatment SUV in PD, SD, PR and CR groups.....	68
Fig. (39):	Box-and-whisker plots of Δ SUV in PD, SD, PR and CR groups	68
Fig. (40):	Scatter diagram displaying the strong positive correlation between Δ SUV and Δ SIZE in all patients	70
Fig. (41):	Case 1	71
Fig. (42):	Case 2	73
Fig. (43):	Case 3	765
Fig. (44):	Case 4	77
Fig. (45):	Case 5	79
Fig. (46):	Case 6.....	81
Fig. (47):	Case 7	83
Fig. (48):	Case 8	86

INTRODUCTION

Lung cancer is the most common cancer; despite major advances in prevention and treatment, it remains the leading cause of cancer-related death worldwide. Over 85% of cases are of non-small cell lung cancer (NSCLC), while the remainder are small cell lung cancers (SCLCs) (*Kitajima et al., 2016*).

Treatment of lung cancer consists of a combination of surgery, chemotherapy and radiation therapy depending on pathology and stage of the disease. Prognosis of lung cancer is generally poor with five year overall survival rate of about 15% (*Khiewvan et al., 2016*).

The goals of therapy for patients with NSCLC depend on the stage of disease: for patients with stage I to III disease, the goal is cure, whereas, for those with stage IV disease, the goals are palliation of symptoms and prolongation of life. The goal of therapy in patients with LS-SCLC is cure, which can be achieved through combined modality therapy with chemotherapy plus radiation (*Gadgeel et al., 2012*).

A multidisciplinary approach including the use of advanced imaging techniques for early accurate staging of disease and delivery of treatment is needed to avoid futile treatments and improve overall survival, which, in turn, influence the patient's quality of life (*Sheikhbahaei et al., 2017*).

Combining CT with FDG PET is expected to improve accuracy and early diagnosis of progressive disease because changes in cellular metabolism occur more rapidly than do changes in tumor size. By providing information on the metabolic activity of tumor cells, FDG PET has become a powerful tool in assessing treatment response (*Sheikhbahaei et al., 2017*).

Initial disease staging in newly diagnosed NSCLC can correctly differentiate patients with potentially curable disease from those indicated for palliative therapy. 18F-FDG PET/ CT has greater staging accuracy than either of the modalities alone because of the improved detection of additional lymph node involvement or distant metastasis (*Kitajima et al., 2016*).

Restaging after therapy depending only on morphologic changes usually needs a lot of time to detect any changes (several weeks to months). Also it may be incorrect because of edema and peri-tumoral scar tissue formation which may mask tumor regression. As a result of this, many patients are sometimes treated without any benefit from the therapy bearing unacceptable side effects and costly treatment. Considering the above mentioned reasons, the morphologic response only is not ideal (*Koma et al., 2013*).

18 F-FDG PET-CT is largely used in oncology, especially for monitoring the response to treatment. The imaging of changes in glucose metabolism, as reflected by

cellular uptake and trapping of 18 F-FDG, can provide a response assessment that is both more-timely and more accurate than that provided by standard morphological imaging. Furthermore, the residual metabolic activity of tumors after radiotherapy, as measured by 18 F-FDG uptake, has been shown to correlate with the pathologic response, and to be a significant prognostic factor for survival in patients with NSCLC (*Massacesi et al., 2012*).

Early prediction of tumor response to treatment is of particular interest in patients with advanced NSCLC. The majority of NSCLC patients presents with unresectable disease (stage IIIB, IV) and undergo palliative therapy with platinum-based chemotherapy regimens and in 30% of patients, first-line chemotherapy is unsuccessful; therefore, a significant number of the patients undergo multiple-week-toxic therapy without any benefit. Early prediction of tumor response would allow physicians to provide patients with non-responsive tumors with alternative forms of treatment with greater time efficiency (*Ordu et al., 2014*).

18F- fluorodeoxyglucose (FDG) is the most common radiotracer used in PET imaging. Studies have shown that the degree of 18F-FDG uptake by the tumor, as assessed with maximum standardized uptake value (SUVmax), is a significant predictive factor in treatment response of lung cancer. SUVmax has been widely used as an indicator of tumor metabolic activity because of its convenience of measurement (*Huang et al., 2014*).

SUV is calculated by normalizing the attenuation corrected FDG uptake in a lesion to the injected dose and body weight. Maximum standardized uptake value (SUVmax) represents a voxel with the maximum FDG uptake in the region of interest (ROI) (*Lee et al., 2016*).

Radiological follow-up of bronchogenic carcinoma to assess therapy response using CT established by using Response Evaluation Criteria In Solid Tumor (RECIST criteria) depending on size change and reduction of the tumoral mass. However, structural changes may occur late after positive biological response, giving a false impression of stationary course. Also, central necrosis or hemorrhage secondary to treatment may cause an increase in the tumor mass size, giving a pseudoprogression result in CT (*Osman and Korashi, 2020*).